eligibility_summary
Inclusion: adults (≥18) with unresectable/metastatic relapsed/refractory clear cell RCC, cervical, pancreatic adenocarcinoma, esophageal carcinoma, or malignant pleural mesothelioma, ECOG 0–1, adequate renal, liver, cardiac, and pulmonary function, contraception required through 12 months after CTX131. Exclusion: prior anti-CD70 therapy, certain CNS/cardiac/pulmonary disease, uncontrolled infection, active HIV/HBV/HCV, immunodeficiency/autoimmune on immunosuppression, pregnant/breastfeeding.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Intervention: CTX131, an allogeneic (off‑the‑shelf) CD70‑directed chimeric antigen receptor (CAR) T‑cell therapy engineered ex vivo with CRISPR‑Cas9. Type: gene‑edited cellular immunotherapy (biological). Mechanism of action: CAR enables antigen‑specific recognition of CD70 on tumor cells, leading to T‑cell activation, cytokine release, and direct cytotoxic killing, CRISPR‑Cas9 edits support use in the allogeneic setting. Administration: IV infusion after lymphodepleting chemotherapy. Targets/cells/pathways: CD70‑expressing malignant cells in clear cell renal cell carcinoma, cervical carcinoma, esophageal carcinoma, pancreatic adenocarcinoma, and malignant pleural mesothelioma, harnesses CAR‑mediated T‑cell effector pathways to eliminate CD70+ tumor cells. Phase 1/2, dose‑escalation/expansion, open‑label, multicenter.